Cargando…

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

Detalles Bibliográficos
Autores principales:	Trojanec, R, Koudelakova, V, Bouchalova, K, Radova, L, Ondryasova, H, Krejci, E, Megova, M, Cizkova, M, Mlcochova, S, Melichar, B, Hajduch, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247057/ http://dx.doi.org/10.1186/bcr3030

Ejemplares similares

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Delineation of anthracyclines and herceptin induced cardiotoxicity using contrast enhanced CMR
por: Hamirani, Yasmin S, et al.
Publicado: (2014)

Nestin and collagen triple helix repeat containing 1 in breast cancer progression
por: Kharaishvili, G, et al.
Publicado: (2011)

Herceptin in clinical use - early 2000
por: Vogel, CL
Publicado: (2000)

Transgenic models are predictive: the herceptin and flavopiridol experience
por: Schmidt, E
Publicado: (2003)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2006)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2008)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer
por: Watters, A D, et al.
Publicado: (2002)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
por: Swofford, Brenen P., et al.
Publicado: (2017)

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
por: Stahl, Phillip, et al.
Publicado: (2015)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Constitutive CCND1/CDK2 Activity Substitutes for p53 Loss, or MYC or Oncogenic RAS Expression in the Transformation of Human Mammary Epithelial Cells
por: Junk, Damian J., et al.
Publicado: (2013)

Myc-Foxo, a link between glutaminolysis and autophagy
por: Zola, Sheri, et al.
Publicado: (2012)

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
por: Sassen, Andrea, et al.
Publicado: (2009)

The role of Herceptin in early breast cancer
por: Subramanian, Ashok, et al.
Publicado: (2008)

Mild hyperthermia influence on Herceptin(®) properties
por: Escoffre, Jean-Michel, et al.
Publicado: (2015)

Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations
por: Yasumi, Masato, et al.
Publicado: (2020)

The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study
por: Kalita, Ondrej, et al.
Publicado: (2021)

Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer
por: Shajahan-Haq, Ayesha, et al.
Publicado: (2014)

Value of CD44 immunostaining (IHC) as a surrogate in the differentiation of MYC-positive Burkitt lymphoma (BL) and Burkitt lymphoma-like (BLL) from MYC-negative Diffuse Large B-Cell Lymphoma (DLBCL) in a resource constrained clinical setting
por: Ayers, LW, et al.
Publicado: (2009)

MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma
por: Yan, Xiao, et al.
Publicado: (2020)

P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA
por: Brown, F., et al.
Publicado: (2022)

MycPermCheck: the Mycobacterium tuberculosis permeability prediction tool for small molecules
por: Merget, Benjamin, et al.
Publicado: (2013)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Serum level of growth-related oncogene alpha during abdominal aortic aneurysm repair in humans
por: Jedynak, M, et al.
Publicado: (2008)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
por: Nemecek, Radim, et al.
Publicado: (2016)

Herceptin clinical trials: past, present and future
por: Vogel, CL
Publicado: (2001)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Prevalence of human papillomavirus infection in oocyte donors and women treated for infertility: An observational laboratory-based study()
por: Jaworek, Hana, et al.
Publicado: (2019)

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
por: GRELL, PETER, et al.
Publicado: (2012)

Abrogation of Brd4 cellular function contributes to the oncogenic mechanisms of translocation t(15;19)-associated carcinoma
por: Wang, Ranran, et al.
Publicado: (2013)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

CD5-negative Blastoid Variant Mantle Cell Lymphoma with Complex CCND1/IGH and MYC Aberrations
por: Seok, Yoonmi, et al.
Publicado: (2012)

Consequences of oncogenic isocitrate dehydrogenase mutations and 2-hydroxyglutarate production in prostate epithelium
por: Over, Jon A, et al.
Publicado: (2013)

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014)

Safety of trastuzumab (Herceptin(®)) during pregnancy: two case reports
por: Goodyer, Matthew J, et al.
Publicado: (2009)

Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_unk7orjut633ellef4se3d6utt